Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.
Authors
Chen, RAllibone, Suzanne
Bartlett, N
Brice, P
Chen, A
Pose, K
Rich, L
Bonthapally, V
Garfin, P
Fanale, M
Affiliation
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USAIssue Date
2016
Metadata
Show full item recordAbstract
Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are becoming increasingly important and can help inform treatment decisions to enhance care of cancer patients.Citation
Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. 2016, 9:2027-34 Onco Targets TherJournal
OncoTargets and TherapyDOI
10.2147/OTT.S96175PubMed ID
27103829Type
ArticleLanguage
enISSN
1178-6930ae974a485f413a2113503eed53cd6c53
10.2147/OTT.S96175